Drug Discovery
ByAbbVie’s $380M North Chicago API Expansion—300 Jobs, AI Boost for Neuroscience/Obesity Pipeline
Published by BioNextAI Media – AbbVie is injecting $380 million into two new active pharmaceutical ingredient (API) facilities at…
Pfizer’s 1,200-GPU AI Blitz—$500M Bet to Slash 18-24 Month Timelines Across Pharma Value Chain
Published by BioNextAI Media – Pfizer is deploying over 1,200 NVIDIA H100/H200 GPUs in a $500-600 million infrastructure overhaul,…
BioNextAI Media Report: Merck-Mayo Clinic AI Pact—5 Petabytes of Data to Slash Drug Timelines 30-50% Amid R&D Arms Race
Published by BioNextAI Media – Merck has forged a high-octane research collaboration with Mayo Clinic, fusing 5 petabytes of…
BioNextAI Media Report: Keytruda’s Ovarian Cancer Combo Triumph—28% Survival Boost Lifts Merck Stock 4% Amid Patent Shadow
Published by BioNextAI Media – Merck’s KEYTRUDA (pembrolizumab) delivered compelling Phase 3 data from combination regimens in ovarian cancer,…
How Does AbbVie Pioneer Oncology Transformation While Sustaining Immunology Leadership Through 2030?
AbbVie strategically positions for multi-franchise dominance through its $59B immunology base (Skyrizi/Rinvoq offsetting Humira’s $17B erosion) while aggressively building oncology leadership via ImmunoGen Elahere acquisition ($10B…
How Does Johnson & Johnson Weaponize Oncology Supremacy for $50 Billion Revenue by 2030?
Johnson & Johnson orchestrates a “full-spectrum oncology domination” strategy across its Innovative Medicine division, positioning for #1 global oncology leadership…
